Online inquiry

IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6496MR)

This product GTTS-WQ6496MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6496MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9526MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ6470MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ3162MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ2779MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ6613MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ2017MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ2772MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ2000MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS-22CE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW